公开(公告)号：US10913792B2

公开(公告)日：2021-02-09

申请号：US15880726

申请日：2018-01-26

Applicant: MORPHOSYS AG

Inventor： Stefan Hartle ,  Stephane Leclair ,  Amgad Shebl ,  Stefan Steidl ,  Bodo Brocks ,  Daniela Della Ducata ,  Kai Rosport

IPC: C07K16/24 ,  A61K31/519 ,  A61K39/395 ,  A61K39/00

Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

公开(公告)号：US20190322742A1

公开(公告)日：2019-10-24

申请号：US16310555

申请日：2017-06-27

Applicant: MorphoSys AG

Inventor： Patrick Garidel ,  Andreas Langer ,  Martin Hessling ,  Daniel Weinfurtner ,  Bodo Brocks

IPC: C07K16/28 ,  A61K9/19 ,  A61K31/715 ,  A61K47/36 ,  A61K47/54

Abstract: The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody.

公开(公告)号：US11352423B2

公开(公告)日：2022-06-07

申请号：US16310555

申请日：2017-06-27

Applicant: MorphoSys AG

Inventor： Patrick Garidel ,  Andreas Langer ,  Martin Hessling ,  Daniel Weinfurtner ,  Bodo Brocks

IPC: C07K16/28 ,  A61K47/54 ,  A61K9/19 ,  A61K47/36 ,  A61K31/715

Abstract: The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody.